文献速递腹部泌尿生殖技术与安全PETMRCT

神经内分泌肿瘤患者PET/MRI快速非增强腹部检查方案:与多期增强PET/CT的比较

Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT.
PubMed 文献 · Radiol Med · 2018-06-30

回顾性分析29例神经内分泌肿瘤患者同日行生长抑素受体特异性示踪剂PET/CT与PET/MRI,评估四种非增强PET/MRI方案对病灶检出的效果。以PET/MRI与PET/CT(含随访)共识读片为参考标准,方案IV(PET+T2 HASTE+T2 TSE+DWI)总检出率与PET/CT相当(91.5%/92.9% vs 89.7%),肝脏和骨病灶等于或优于PET/CT,但胰腺、小肠及淋巴结转移灶低于PET/CT。

要点

  • 方案IV(T2 HASTE+T2 TSE+DWI)总病灶检出率与多期增强PET/CT相当。
  • 肝脏病灶(平均直径1.9 cm)检出率98%/98% vs PET/CT 85%。
  • 骨病灶(平均直径1.5 cm)检出率100%/95% vs PET/CT 100%。

核心结论

  • 包含T2 HASTE、T2 TSE和DWI的非增强MR方案用于生长抑素受体PET/MRI时,病灶检出效果似乎与多期增强PET/CT相当,可能作为有效替代方案,例如用于不可切除NET合并肾衰竭患者的随访检查。

研究设计与样本

  • 回顾性分析29例患者(12例男性,年龄57±13岁),同日先后行PET/CT和PET/MRI;两名读片者独立评估四种PET/MRI方案;以PET/MRI与PET/CT(含随访检查)的共识读片为基于病灶分析的参考标准;评估病灶大小。

关键影像表现/征象

  • 方案IV在两名读片者的总检出率分别为91.5%和92.9%,PET/CT为89.7%。
  • 肝脏病灶(平均直径1.9 cm)方案IV检出率98%/98%,PET/CT为85%。
  • 骨病灶(平均直径1.5 cm)方案IV检出率100%/95%,PET/CT为100%。
  • 胰腺病灶(平均直径1.3 cm)、小肠病灶(平均直径0.5 cm)及淋巴结转移灶(平均直径1.8 cm)方案IV检出率低于PET/CT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate fast non-enhanced protocols for abdominal PET/MRI in comparison to contrast-enhanced PET/CT with somatostatin receptor (SSR)-specific radiotracers regarding effectiveness of lesion detection in NET patients.

METHODS: This was a retrospective analysis of 29 patients (12 male, 57 ± 13 years) who underwent PET/CT and subsequently PET/MRI at the same day. Two readers evaluated independently four PET/MRI setups: (I) PET + T2 Half Fourier Acquisition Single Shot Turbo Spin Echo (T2 HASTE), (II) PET + T2 HASTE + T2-weighted spin-echo sequence (T2 TSE), III) PET + T2 HASTE + Diffusion Weighted Imaging (DWI) and (IV) PET + T2 HASTE + T2 TSE + DWI. A consensus reading of PET/MRI and PET/CT including follow-up examinations served as the reference standard for lesion-based analysis. Lesion sizes were assessed.

RESULTS: Setup IV provided comparable overall detection rates as PET/CT in both readers: PET/MRI 91.5%/92.9% versus 89.7% in PET/CT. In liver and bone lesions (mean diameter: 1.9 and 1.5 cm), PET/MRI was equal or superior to PET/CT: 98%/98% versus 85% in PET/CT; 100%/95% versus 100% in PET/CT, but inferior in pancreatic lesions, small bowel lesions and lymph node metastases (mean diameter: 1.3, 0.5 and 1.8 cm).

CONCLUSION: A non-enhanced MR protocol comprising T2 HASTE, T2 TSE and DWI for SSR-PET/MRI seems to provide comparable effectiveness in lesions detection as multiphase contrast-enhanced PET/CT. It might, therefore, serve as valid alternative, e.g., for follow-up examinations in patients with unresectable NET and kidney failure.

来源:Radiol Med,查看原文。版权归原作者所有。

引用

  1. Seith F, Schraml C, Reischl G, et al. Fast non-enhanced abdominal examination protocols in PET/MRI for patients with neuroendocrine tumors (NET): comparison to multiphase contrast-enhanced PET/CT. Radiol Med. 2018. PMID: 29961229. doi:10.1007/s11547-018-0917-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。